Alnylam Pharmaceuticals, Inc.
POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
Last updated:
Abstract:
The invention relates to polynucleotide agents targeting the complement component C5 gene, and methods of using such polynucleotide agents to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
Status:
Application
Type:
Utility
Filling date:
28 Jun 2021
Issue date:
26 May 2022